



## Charles DeBattista

Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology - Adult)

### CLINICAL OFFICES

- **Psychiatry Department**

401 Quarry Rd Rm 2303

MC 5723

Stanford, CA 94305

**Tel** (650) 498-9111

**Fax** (650) 724-9900

### Bio

---

### CLINICAL FOCUS

- Psychiatry
- Clinical Psychopharmacology
- Resistant Depression
- Neuromodulation

### ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Psychiatry and Behavioral Sciences
- Member, Wu Tsai Neurosciences Institute

### HONORS AND AWARDS

- Teacher of the Year, Dept. Of Psychiatry (1998, 2000, 2001)
- America's Best Doctors; Psychiatry, Best Doctors (2009-2015)

### PROFESSIONAL EDUCATION

- Fellowship: Stanford University Psychiatry and Behavioral Sciences (1993) CA
- Residency: Stanford University Adult Psychiatry Residency (1993) CA
- Internship: Stanford University Adult Psychiatry Residency (1990) CA
- Medical Education: University of California at San Francisco School of Medicine (1989) CA
- Board Certification: Psychiatry, American Board of Psychiatry and Neurology (1995)
- DMH, UCSF/UC Berkeley , Mental Health (1986)
- MD, UCSF , Medicine (1989)

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Treatment resistant depression.

Novel biological interventions in the treatment of mental illness.

Anti-glucocorticoid drugs in the treatment of mood disorders.

Augmentation strategies in the treatment of depression.

### CLINICAL TRIALS

- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD, Recruiting
- Treatment Trial for Psychogenic Nonepileptic Seizures, Recruiting
- Functional MRI Before and After Treatment for Depression, Not Recruiting
- Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder, Not Recruiting
- Radiosurgical Neuromodulation for Refractory Depression, Not Recruiting
- Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression, Not Recruiting

## Teaching

---

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Psychiatry and Behavioral Science (Fellowship Program)

## Publications

---

### PUBLICATIONS

- **Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.** *The New England journal of medicine*  
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Bruschi, D., Burke, L., Campbell-Coker, K., Carhart-Harris, et al  
2022; 387 (18): 1637-1648
- **A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings.** *Journal of affective disorders*  
McInnes, L. A., Qian, J. J., Gargeya, R. S., DeBattista, C., Heifets, B. D.  
1800
- **Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder.** *Psychiatry research*  
Parikh, S. V., Law, R. A., Hain, D. T., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Forester, B. P., Shelton, R. C., Macaluso, M., Cogan, E. S., Brown, K., Lewis, et al  
1800; 308: 114354
- **Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.** *The American journal of psychiatry*  
Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, et al  
2021: appiajp202120101429
- **The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.** *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*  
Feeney, A., Hock, R. S., Freeman, M. P., Flynn, M., Hoepfner, B., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., DeBattista, C., Ionescu, D. F., Fava, M., Papakostas, et al  
2021; 49: 122-132

- **Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial.** *CNS spectrums*  
Parikh, S. V., Khazanov, G. K., Thase, M. E., Rothschild, A. J., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Shelton, R. C., Macaluso, M., Li, J., Yu, K., Jablonski, et al  
2021; 26 (2): 169-170
- **The Black Book of Psychotropic Dosing and Monitoring.** *Psychopharmacology bulletin*  
DeBattista, C., Schatzberg, A. F.  
2021; 51 (1): 8–58
- **Raising the Quality of Psychopharmacology Clinical Psychiatric Practice: Elements of Good Psychopharmacology Care.** *Journal of clinical psychopharmacology*  
Glick, I. D., Balon, R., DeBattista, C.  
2021; 42 (1): 3-6
- **Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.** *Psychiatry research*  
Rothschild, A. J., Parikh, S. V., Hain, D., Law, R., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Shelton, R. C., Macaluso, M., Brown, K., Lewis, et al  
2020; 296: 113649
- **Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) (vol 25, pg 1592, 2020) MOLECULAR PSYCHIATRY**  
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoepfner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrrough, J., DeBattista, C., Schatzberg, et al  
2020; 25 (7): 1604
- **Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) MOLECULAR PSYCHIATRY**  
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoepfner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrrough, J., DeBattista, C., Schatzberg, et al  
2020; 25 (7): 1592–1603
- **Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression.** *The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry*  
Forester, B. P., Parikh, S. V., Weisenbach, S., Ajilore, O., Vahia, I., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Shelton, R. C., Macaluso, M., Li, et al  
2020
- **Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.** *Psychiatry research*  
Shelton, R. C., Parikh, S. V., Law, R. A., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Macaluso, M., Hain, D. T., Aguilar, A. L., Brown, et al  
2020; 290: 113017
- **COMBINATORIAL PHARMACOGENETIC TESTING IMPROVES RESPONSE AND REMISSION FOR PATIENTS OVER 65 WITH DEPRESSION WHO HAVE FAILED ONE MEDICATION TRIAL**  
Brown, L., Forester, B., Parikh, S., Weisenbach, S., Ajilore, O., Vahia, I., Rothschild, A., Thase, M., Dunlop, B., DeBattista, C., Conway, C., Shelton, R., Macaluso, et al  
ELSEVIER SCIENCE INC.2020: S151–S152
- **Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression.** *The American journal of psychiatry*  
Cole, E. J., Stimpson, K. H., Bentzley, B. S., Gulser, M. n., Cherian, K. n., Tischler, C. n., Nejad, R. n., Pankow, H. n., Choi, E. n., Aaron, H. n., Espil, F. M., Pannu, J. n., Xiao, et al  
2020: appiajp201919070720
- **150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression.** *CNS spectrums*  
Dunlop, B. W., Parikh, S. V., Patel, M. n., Rothschild, A. J., Thase, M. E., DeBattista, C. n., Conway, C. R., Forester, B. P., Shelton, R. C., Macaluso, M. n., Li, J. n., Brown, K. n., Brown, et al  
2020; 25 (2): 295–96
- **Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.** *The Journal of clinical psychiatry*

- Thase, M. E., Parikh, S. V., Rothschild, A. J., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, K., Jablonski, et al  
2019; 80 (6)
- **COMBINATORIAL PHARMACOGENOMIC TESTING IMPROVES OUTCOMES FOR PATIENTS TAKING MEDICATIONS WITH GENE-DRUG INTERACTIONS IN A RANDOMIZED, CONTROLLED TRIAL**  
Thase, M., Parikh, S., Rothschild, A., Dunlop, B., DeBattista, C., Conway, C., Forester, B., Mondimore, F., Shelton, R., Macaluso, M., Li, J., Brown, K., Brown, et al  
ELSEVIER.2019: S132–S133
  - **Response to: Goldberg et al. and Severance et al. letters to the editor the clinical significance of improving remission over standard of care - The reality of treatment resistant-based therapies.** *Journal of psychiatric research*  
Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, et al  
2019
  - **Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study** *JOURNAL OF PSYCHIATRIC RESEARCH*  
Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, et al  
2019; 111: 59–67
  - **Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression** *JOURNAL OF PSYCHIATRIC RESEARCH*  
Freeman, M. P., Papakostas, G. I., Hoepfner, B., Mazzone, E., Judge, H., Cusin, C., Mathew, S., Sanacora, G., Iosifescu, D., DeBattista, C., Trivedi, M. H., Fava, M.  
2019; 110: 166–71
  - **Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression** *DEPRESSION AND ANXIETY*  
Salloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoepfner, B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., DeBattista, C., Ionescu, et al  
2019; 36 (3): 235–43
  - **Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression.** *Journal of psychiatric research*  
Freeman, M. P., Papakostas, G. I., Hoepfner, B., Mazzone, E., Judge, H., Cusin, C., Mathew, S., Sanacora, G., Iosifescu, D., DeBattista, C., Trivedi, M. H., Fava, M.  
2019; 110: 166–71
  - **Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).** *Molecular psychiatry*  
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoepfner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrrough, J., DeBattista, C., Schatzberg, et al  
2019
  - **Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study.** *Journal of psychiatric research*  
Greden, J. F., Parikh, S. V., Rothschild, A. J., Thase, M. E., Dunlop, B. W., DeBattista, C., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M., Li, J., Brown, et al  
2019; 111: 59–67
  - **Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.** *Journal of affective disorders*  
Salloum, N. C., Fava, M. n., Hock, R. S., Freeman, M. P., Flynn, M. n., Hoepfner, B. n., Cusin, C. n., Iosifescu, D. V., Trivedi, M. H., Sanacora, G. n., Mathew, S. J., DeBattista, C. n., Ionescu, et al  
2019; 260: 131–39
  - **Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial.** *BMC psychiatry*  
Dunlop, B. W., Parikh, S. V., Rothschild, A. J., Thase, M. E., DeBattista, C. n., Conway, C. R., Forester, B. P., Mondimore, F. M., Shelton, R. C., Macaluso, M. n., Logan, J. n., Traxler, P. n., Li, et al  
2019; 19 (1): 420
  - **Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.** *Depression and anxiety*

- Salloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoepfner, B., Hock, R. S., Cusin, C., Iosifescu, D. V., Trivedi, M. H., Sanacora, G., Mathew, S. J., DeBattista, C., Ionescu, et al  
2018
- **Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).** *Molecular psychiatry*  
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoepfner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., Murrough, J., DeBattista, C., Schatzberg, et al  
2018
  - **Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein** *AMERICAN JOURNAL OF PSYCHIATRY*  
O'Connell, C. P., Goldstein-Piekarski, A. N., Nemeroff, C. B., Schatzberg, A. F., DeBattista, C., Carrillo-Roa, T., Binder, E. B., Dunlop, B. W., Craighead, W., Mayberg, H. S., Williams, L. M.  
2018; 175 (3): 251–61
  - **The Black Book of Psychotropic Dosing and Monitoring.** *Psychopharmacology bulletin*  
Schatzberg, A. F., Charles, D.  
2018; 48 (1): 64–153
  - **Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.** *The American journal of psychiatry*  
O'Connell, C. P., Goldstein-Piekarski, A. N., Nemeroff, C. B., Schatzberg, A. F., DeBattista, C. n., Carrillo-Roa, T. n., Binder, E. B., Dunlop, B. W., Craighead, W. E., Mayberg, H. S., Williams, L. M.  
2018; 175 (3): 251–61
  - **Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial.** *The lancet. Psychiatry*  
Holtzheimer, P. E., Husain, M. M., Lisanby, S. H., Taylor, S. F., Whitworth, L. A., McClintock, S. n., Slavin, K. V., Berman, J. n., McKhann, G. M., Patil, P. G., Rittberg, B. R., Abosch, A. n., Pandurangi, et al  
2017; 4 (11): 839–49
  - **Psychostimulants and Wakefulness-Promoting Agents** *AMERICAN PSYCHIATRIC ASSOCIATION PUBLISHING TEXTBOOK OF PSYCHOPHARMACOLOGY, 5TH EDITION*  
DeBattista, C., Schatzberg, A. F., Nemeroff, C. B.  
2017: 1083–1103
  - **Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression** *TRANSLATIONAL PSYCHIATRY*  
Williams, L. M., DeBattista, C., Duchemin, A., Schatzberg, A. F., Nemeroff, C. B.  
2016; 6
  - **Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report** *EUROPEAN NEUROPSYCHOPHARMACOLOGY*  
van Dinteren, R., Arns, M., Kenemans, L., Jongasma, M. L., Kessels, R. P., Fitzgerald, P., Fallahpour, K., DeBattista, C., Gordon, E., Williams, L. M.  
2015; 25 (11): 1981-1990
  - **ABC1 (MDR1) predicts remission on P-gp substrates in chronic depression** *PHARMACOGENOMICS JOURNAL*  
Ray, A., Tennakoon, L., Keller, J., Sarginson, J. E., Ryan, H. S., Murphy, G. M., Lazzeroni, L. C., Trivedi, M. H., Kocsis, J. H., DeBattista, C., Schatzberg, A. F.  
2015; 15 (4): 332-339
  - **Frontal and rostral anterior cingulate (rACC) theta EEG in depression: Implications for treatment outcome?** *EUROPEAN NEUROPSYCHOPHARMACOLOGY*  
Arns, M., Etkin, A., Hegerl, U., Williams, L. M., DeBattista, C., Palmer, D. M., Fitzgerald, P. B., Harris, A., deBeuss, R., Gordon, E.  
2015; 25 (8): 1190-1200
  - **ABC1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial** *AMERICAN JOURNAL OF PSYCHIATRY*  
Schatzberg, A. F., DeBattista, C., Lazzeroni, L. C., Etkin, A., Murphy, G. M., Williams, L. M.  
2015; 172 (8): 751-759
  - **Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report** *JOURNAL OF AFFECTIVE DISORDERS*  
Day, C. V., Gatt, J. M., Etkin, A., DeBattista, C., Schatzberg, A. F., Williams, L. M.  
2015; 176: 141-150
  - **The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment.** *Journal of psychiatric research*

- Saveanu, R., Etkin, A., Duchemin, A., Goldstein-Piekarski, A., Gyurak, A., DeBattista, C., Schatzberg, A. F., Sood, S., Day, C. V., Palmer, D. M., Rekshan, W. R., Gordon, E., Rush, et al  
2015; 61: 1-12
- **Impairment and distress patterns distinguishing the melancholic depression subtype: An iSPOT-D report.** *Journal of affective disorders*  
Day, C. V., John Rush, A., Harris, A. W., Boyce, P. M., Rekshan, W., Etkin, A., DeBattista, C., Schatzberg, A. F., Arnow, B. A., Williams, L. M.  
2015; 174: 493-502
  - **ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.** *The pharmacogenomics journal*  
Ray, A., Tennakoon, L., Keller, J., Sarginson, J. E., Ryan, H. S., Murphy, G. M., Lazzeroni, L. C., Trivedi, M. H., Kocsis, J. H., DeBattista, C., Schatzberg, A. F.  
2014
  - **ABCB1 Genetic Variants and Neurocognitive Function Predict Antidepressant Outcomes**  
Schatzberg, A., DeBattista, C., Etkin, A., Williams, L.  
NATURE PUBLISHING GROUP.2014: S521-S522
  - **Measuring severe adverse events and medication selection using a "PEER Report" for nonpsychotic patients: a retrospective chart review** *NEUROPSYCHIATRIC DISEASE AND TREATMENT*  
Hoffman, D. A., DeBattista, C., Valuck, R. J., Iosifescu, D. V.  
2012; 8: 277-284
  - **The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression** *JOURNAL OF PSYCHIATRIC RESEARCH*  
DeBattista, C., Kinrys, G., Hoffman, D., Goldstein, C., Zajecka, J., Kocsis, J., Teicher, M., Potkin, S., Preda, A., Multani, G., Brandt, L., Schiller, M., Iosifescu, et al  
2011; 45 (1): 64-75
  - **Response to Dr. Tsai's letter to the Editor - The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression** *JOURNAL OF PSYCHIATRIC RESEARCH*  
DeBattista, C., Hoffman, D. A.  
2011; 45 (1): 134-35
  - **Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.** *Current drug safety*  
DeBattista, C., DeBattista, K.  
2010; 5 (3): 263-266
  - **A Multisite Trial of Mifepristone for the Treatment of Psychotic Depression: A Site-by-Treatment Interaction (vol 30, pg 284, 2009)** *CONTEMPORARY CLINICAL TRIALS*  
Blasey, C. M., DeBattista, C., Roe, R., Block, T., Belanoff, J. K.  
2010; 31 (1): 134-134
  - **Safety Considerations of the Use of Second Generation Antipsychotics in the Treatment of Major Depression: Extrapyramidal and Metabolic Side Effects** *CURRENT DRUG SAFETY*  
DeBattista, C., DeBattista, K.  
2010; 5 (3): 263-66
  - **A Multisite Trial of Mifepristone for the Treatment of Psychotic Depression: A Site-by-Treatment Interaction (vol 30, pg 284, 2009)** *CONTEMPORARY CLINICAL TRIALS*  
Blasey, C. M., DeBattista, C., Roe, R., Block, T., Belanoff, J. K.  
2009; 30 (5): 497-497
  - **Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function** *PSYCHONEUROENDOCRINOLOGY*  
Gomez, R. G., Posener, J. A., Keller, J., DeBattista, C., Solvason, B., Schatzberg, A. F.  
2009; 34 (7): 1012-1018
  - **A multisite trial of mifepristone for the treatment of psychotic depression: A site-by-treatment interaction** *CONTEMPORARY CLINICAL TRIALS*  
Blasey, C. M., DeBattista, C., Roe, R., Block, T., Belanoff, J. K.  
2009; 30 (4): 284-288
  - **Utility of Atypical Antipsychotics in the Treatment of Resistant Unipolar Depression** *CNS DRUGS*  
DeBattista, C., Hawkins, J.

2009; 23 (5): 369-377

- **Sildenafil treatment of women with antidepressant-associated sexual dysfunction - A randomized controlled trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Nurnberg, H. G., Hensley, P. L., Heiman, J. R., Croft, H. A., DeBattista, C., Paine, S.  
2008; 300 (4): 395-404
- **Depression and smoking cessation: does the evidence support psychiatric practice?** *Neuropsychiatric disease and treatment*  
Lembke, A., Johnson, K., DeBattista, C.  
2007; 3 (4): 487-493
- **Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness.** *Annals of clinical psychiatry*  
Fava, M., Thase, M. E., DeBattista, C., Doghramji, K., Arora, S., Hughes, R. J.  
2007; 19 (3): 153-159
- **Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression** *43rd Annual Meeting of the American-College-of-Neuropsychopharmacology*  
DeBattista, C., Belanoff, J., Glass, S., Khan, A., Horne, R. L., Blasey, C., Carpenter, L. L., Alva, G.  
ELSEVIER SCIENCE INC.2006: 1343-49
- **The neuropsychological profile of psychotic major depression and its relation to cortisol** *BIOLOGICAL PSYCHIATRY*  
Gomez, R. G., Fleming, S. H., Keller, J., Flores, B., Kenna, H., DeBattista, C., Solvason, B., Schatzberg, A. F.  
2006; 60 (5): 472-478
- **The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats** *BEHAVIOURAL BRAIN RESEARCH*  
Beebe, K. L., Block, T., DeBattista, C., Blasey, C., Belanoff, J. K.  
2006; 171 (2): 225-229
- **Augmentation and combination strategies for depression** *158th Annual Scientific Meeting of the American-Psychiatric-Association*  
DeBattista, C.  
SAGE PUBLICATIONS LTD.2006: 11-18
- **Serious adverse events and the Modafinil Augmentation Study - Reply** *CNS SPECTRUMS*  
Thase, M. E., Fava, M., DeBattista, C., Arora, S., Hughes, R. J.  
2006; 11 (5): 340-342
- **An open maintenance trial using low frequency transcranial magnetic stimulation for treatment resistant unipolar and bipolar depression** *61st Annual Convention of the Society-of-Biological-Psychiatry*  
Solvason, H. B., Kenna, H., Katz, M., Lopez, J., Debattista, C.  
ELSEVIER SCIENCE INC.2006: 170S-170S
- **The use of mifepristone in the treatment of neuropsychiatric disorders** *TRENDS IN ENDOCRINOLOGY AND METABOLISM*  
DeBattista, C., Belanoff, J.  
2006; 17 (3): 117-121
- **Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: A 12-week, open-label, extension study** *CNS SPECTRUMS*  
Thase, M. E., Fava, M., Debattista, C., Arora, S., Hughes, R. J.  
2006; 11 (2): 93-102
- **Detecting psychotic major depression using psychiatric rating scales** *JOURNAL OF PSYCHIATRIC RESEARCH*  
Keller, J., Gomez, R. G., Kenna, H. A., Poesner, J., Debattista, C., Flores, B., Schatzberg, A. F.  
2006; 40 (1): 22-29
- **Update on augmentation of antidepressant response in resistant depression.** *Current psychiatry reports*  
DeBattista, C., Lembke, A.  
2005; 7 (6): 435-440
- **The efficacy of divalproex sodium in the treatment of agitation associated with major depression** *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*  
Debattista, C., Solomon, A., Arnow, B., Kendrick, E., Tilston, J., Schatzberg, A. F.

2005; 25 (5): 476-479

- **A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction** *JOURNAL OF CLINICAL PSYCHIATRY*  
DeBattista, C., Solvason, B., Poirier, J., Kendrick, E., Loraas, E.  
2005; 66 (7): 844-848
- **C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.** *Current Alzheimer research*  
DeBattista, C., Belanoff, J.  
2005; 2 (2): 125-129
- **Executive dysfunction in major depressive disorder.** *Expert review of neurotherapeutics*  
DeBattista, C.  
2005; 5 (1): 79-83
- **A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness** *JOURNAL OF CLINICAL PSYCHIATRY*  
Fava, M., Thase, M. E., Debattista, C.  
2005; 66 (1): 85-93
- **A double-blind, placebo controlled trial of C-1073 (mifepristone) in the treatment of psychotic major depression** *43rd Annual Meeting of the American-College-of-Neuropsychopharmacology*  
Debattista, C., Belanoff, J.  
NATURE PUBLISHING GROUP.2004: S98-S98
- **HPA axis activation in major depression and response to fluoxetine: a pilot study** *PSYCHONEUROENDOCRINOLOGY*  
Young, E. A., Altemus, M., Lopez, J. F., Kocsis, J. H., Schatzberg, A. F., Debattista, C., Zubieta, J. K.  
2004; 29 (9): 1198-1204
- **Modafinil as antidepressant augmentation therapy in major depressive disorder**  
Thase, M. E., DeBattista, C., Fava, M.  
ELSEVIER SCIENCE BV.2004: S210-S211
- **Process irregularity of cortisol and adrenocorticotropin secretion in men with major depressive disorder** *PSYCHONEUROENDOCRINOLOGY*  
Posener, J. A., Debattista, C., Veldhuis, J. D., Province, M. A., Williams, G. H., Schatzberg, A. F.  
2004; 29 (9): 1129-1137
- **Modulators of the HPA axis**  
Schatzberg, A. F., DeBattista, C., Flores, B., Posener, J.  
ELSEVIER SCIENCE BV.2004: S9
- **A prospective trial of modafinil as an adjunctive treatment of major depression** *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*  
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., Poirier, J.  
2004; 24 (1): 87-90
- **Seizure duration with remifentanyl/methohexital vs. methohexital alone in middle-aged patients undergoing electroconvulsive therapy** *ACTA ANAESTHESIOLOGICA SCANDINAVICA*  
Smith, D. L., Angst, M. S., Brock-Utne, J. G., Debattista, C.  
2003; 47 (9): 1064-1066
- **Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study** *JOURNAL OF CLINICAL PSYCHIATRY*  
Debattista, C., Doghramji, K., Menza, M. A., Rosenthal, M. H., Fieve, R. R.  
2003; 64 (9): 1057-1064
- **Safety of antidepressants in the elderly.** *Expert opinion on drug safety*  
Sommer, B. R., Fenn, H., Pompei, P., DeBattista, C., Lembke, A., Wang, P., Flores, B.  
2003; 2 (4): 367-383
- **A prospective trial of bupropion SR augmentation of partial and non-responders to Serotonergic antidepressants** *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*



- DeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., Schatzberg, A. F.  
2003; 23 (1): 27-30
- **The timing of electroconvulsive therapy and bispectral index after anesthesia induction using different drugs does not affect seizure duration** *JOURNAL OF CLINICAL ANESTHESIA*  
Lemmens, H. J., Levi, D. C., DeBattista, C., Brock-Utne, J. G.  
2003; 15 (1): 29-32
  - **Fetal heart rate decelerations during ECT-induced seizures: is it important?** *ACTA ANAESTHESIOLOGICA SCANDINAVICA*  
DeBattista, C., Cochran, M., Barry, J. J., Brock-Utne, J. G.  
2003; 47 (1): 101-103
  - **Novel strategies in the treatment of psychotic major depression** *PSYCHIATRIC ANNALS*  
DeBattista, C., Belanoff, J.  
2002; 32 (11): 695-698
  - **The impact on cognitive function of pharmacologic treatments for late-life depression**  
O'Hara, R., Schatzberg, A. F., Kremer, C., Rodrigues, H., DeBattista, C., Murphy, G. M.  
PHYSICIANS POSTGRADUATE PRESS.2002: 1075-76
  - **The status of evidence-based guidelines and algorithms in the treatment of depression** *PSYCHIATRIC ANNALS*  
DeBattista, C., Trivedi, M. H., Kern, J. K., Lembke, A.  
2002; 32 (11): 658-663
  - **A dynamic algorithm for the treatment of psychotic major depression** *PSYCHIATRIC ANNALS*  
DeBattista, C., Rothschild, A. J., Schatzberg, A. F.  
2002; 32 (11): 681-691
  - **An open label trial of C-1073 (mifepristone) for psychotic major depression** *BIOLOGICAL PSYCHIATRY*  
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E. E., Schold, C., Schatzberg, A. F.  
2002; 52 (5): 386-392
  - **Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone** *JOURNAL OF MOLECULAR NEUROSCIENCE*  
Belanoff, J. K., Jurik, J., Schatzberg, L. D., DeBattista, C., Schatzberg, A. F.  
2002; 19 (1-2): 201-206
  - **Delusional major depression: new treatment approaches** *Collegium Internationale Neuro-Psychopharmacologicum (CINP)*  
Schatzberg, A. F., Belanoff, J., DeBattista, C.  
LIPPINCOTT WILLIAMS & WILKINS.2002: S99-S100
  - **Effect of Hypericum perforatum (St John's wort) in major depressive disorder - A randomized controlled trial** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*  
Davidson, J. R., Gadde, K. M., Fairbank, J. A., Krishnan, R. R., Califf, R. M., Binnay, C., Parker, C. B., Pugh, N., Hartwell, T. D., Vitiello, B., Ritz, L., Severe, J., Cole, et al  
2002; 287 (14): 1807-1814
  - **New psychopharmacologic treatment strategies - Response** *ANNALS OF INTERNAL MEDICINE*  
Glick, I. D., DeBattista, C.  
2001; 135 (11): 1008
  - **Cortisol feedback during the HPA quiescent period in patients with major depression** *AMERICAN JOURNAL OF PSYCHIATRY*  
Posener, J. A., DeBattista, C., Williams, G. H., Schatzberg, A. F.  
2001; 158 (12): 2083-2085
  - **Antidepressant effects of hydrocortisone - Dr. DeBattista replies** *AMERICAN JOURNAL OF PSYCHIATRY*  
DeBattista, C.  
2001; 158 (9): 1537
  - **Is electroconvulsive therapy effective for the depressed patient with comorbid borderline personality disorder?** *JOURNAL OF ECT*  
DeBattista, C., Mueller, K.  
2001; 17 (2): 91-98

- **Sertraline versus imipramine to prevent relapse in chronic depression** *JOURNAL OF AFFECTIVE DISORDERS*  
Koran, L. M., Gelenberg, A. J., Kornstein, S. G., Howland, R. H., Friedman, R. A., DeBattista, C., Klein, D., Kocsis, J. H., Schatzberg, A. F., Thase, M. E., Rush, A. J., Hirschfeld, R. M., LaVange, et al  
2001; 65 (1): 27-36
- **Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia** *ANNALS OF INTERNAL MEDICINE*  
Glick, I. D., Suppes, T., DeBattista, C., Hu, R. J., Marder, S.  
2001; 134 (1): 47-60
- **Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: A double-blind, placebo-controlled study** *AMERICAN JOURNAL OF PSYCHIATRY*  
DeBattista, C., Posener, J. A., Kalebzan, B. M., Schatzberg, A. F.  
2000; 157 (8): 1334-1337
- **24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression** *28th Annual Meeting of the International-Society-of-Psychoneuroendocrinology*  
Posener, J. A., DeBattista, C., Williams, G. H., Kraemer, H. C., Kalebzan, B. M., Schatzberg, A. F.  
AMER MEDICAL ASSOC.2000: 755-60
- **Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness** *AMERICAN JOURNAL OF PSYCHIATRY*  
Schatzberg, A. F., Posener, J. A., DeBattista, C., Kalebzan, B. M., Rothschild, A. J., Shear, P. K.  
2000; 157 (7): 1095-1100
- **A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.** *New England journal of medicine*  
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., Trivedi, M. H., Zajecka, J.  
2000; 342 (20): 1462-1470
- **A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression** *NEW ENGLAND JOURNAL OF MEDICINE*  
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., Trivedi, M. H., Zajecka, J., Blalock, et al  
2000; 342 (20): 1462-1470
- **Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression** *JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY*  
DeBattista, C., Solvason, H. B., Breen, J. A., Schatzberg, A. F.  
2000; 20 (2): 274-275
- **Negative-pressure pulmonary edema: A potential hazard in patients undergoing ECT** *JOURNAL OF ECT*  
Cochran, M., DeBattista, C., Schmiesing, C., Brock-Utne, J. G.  
1999; 15 (2): 168-170
- **The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder** *JOURNAL OF CLINICAL PSYCHIATRY*  
Crismon, M. L., Trivedi, M., Pigott, T. A., Rush, A. J., Hirschfeld, R. M., Kahn, D. A., DeBattista, C., Nelson, J. C., Nierenberg, A. A., Sackeim, H. A., Thase, M. E.  
1999; 60 (3): 142-156
- **Phenomenology and treatment of agitation** *Closed Symposium on the Phenomenology and Treatment of Aggression Across Psychiatric Illnesses*  
Schatzberg, A. F., DeBattista, C.  
PHYSICIANS POSTGRADUATE PRESS.1999: 17-20
- **ECT in dissociative identity disorder and comorbid depression** *JOURNAL OF ECT*  
DeBattista, C., Solvason, H. B., Spiegel, D.  
1998; 14 (4): 275-279
- **Serotonergic synergism: The risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs** *Neuroscience Discussion Forum on a Decade of Serotonin Research*  
DeBattista, C., Sofuoglu, M., Schatzberg, A. F.  
ELSEVIER SCIENCE INC.1998: 341-47

- **Developing treatment algorithms for unipolar depression in cyberspace: International Psychopharmacology Algorithm Project (IPAP)** *PSYCHOPHARMACOLOGY BULLETIN*  
Trivedi, M. H., DeBattista, C., Fawcett, J., Nelson, C., Osser, D. N., Stein, D., Jobson, K.  
1998; 34 (3): 355-359
- **Treatment of psychotic depression** *AMERICAN JOURNAL OF PSYCHIATRY*  
DeBattista, C., Solvason, H. B., Belanoff, J., Schatzberg, A.  
1997; 154 (11): 1625-1626
- **Does ketorolac prophylaxis prevent succinylcholine induced myalgias following electroconvulsive therapy?**  
Russo, C. M., DeBattista, C., Barry, J., Samuels, S., BROCKUTNE, J. G.  
LIPPINCOTT WILLIAMS & WILKINS.1997: S20-S20
- **Valproate in the treatment of agitation associated with depression** *PSYCHIATRIC ANNALS*  
Schatzberg, A. F., DeBattista, C., DeGolia, S.  
1996; 26 (7): S470-S473
- **Development of obsessive symptoms during nefazodone treatment** *AMERICAN JOURNAL OF PSYCHIATRY*  
Sofuoglu, M., DeBattista, C.  
1996; 153 (4): 577-578
- **Sertraline or imipramine for chronic depression: 7-month results**  
Koran, L., DeBattista, C., Gelenberg, A., Hirschfeld, R., Keitner, G., Keller, M. B., Klein, D., Kocsis, J. H., Kornstein, S., Schatzberg, A., Thase, M.  
US GOVERNMENT PRINTING OFFICE.1996: 396
- **SUMATRIPTAN PROPHYLAXIS FOR POSTELECTROCONVULSIVE THERAPY HEADACHES** *HEADACHE*  
DeBattista, C., Mueller, K.  
1995; 35 (8): 502-503
- **PHYSICAL SYMPTOMS ASSOCIATED WITH PAROXETINE WITHDRAWAL** *AMERICAN JOURNAL OF PSYCHIATRY*  
DeBattista, C., Schatzberg, A. F.  
1995; 152 (8): 1235-1236
- **PHARMACOTHERAPY OF PERSONALITY-DISORDERS** *CURRENT OPINION IN PSYCHIATRY*  
DeBattista, C., Glick, I. D.  
1995; 8 (2): 102-105
- **AN ALGORITHM FOR THE TREATMENT OF MAJOR DEPRESSION AND ITS SUBTYPES** *PSYCHIATRIC ANNALS*  
DeBattista, C., Schatzberg, A. F.  
1994; 24 (7): 341-347
- **Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.** *Journal of clinical psychopharmacology*  
Freeman, M. P., Hock, R. S., Papakostas, G. I., Judge, H. n., Cusin, C. n., Mathew, S. J., Sanacora, G. n., Iosifescu, D. V., DeBattista, C. n., Trivedi, M. H., Fava, M. n.  
; 40 (3): 287-92